Monica Kraft, MD
Robert and Irene Flinn Professor of Medicine
Chair, Department of Medicine
College of Medicine, Tucson
Deputy Director, Asthma and Airway
Disease Research Center
University of Arizona Health Sciences
Michael Wechsler, MD, MMSc
Director, Asthma Program
Professor of Medicine
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Emily DiMango, MD
Professor of Medicine
Director, John Edsall-John Wood Asthma Center
Director, Adult Cystic Fibrosis Program
Columbia University Medical Center
New York, NY
Mobile + Online on RealCME
This interactive case-based activity will examine treatment strategies for uncontrolled type 2 asthma.
Pulmonologists, allergists, primary care and internal medicine physicians, and others who encounter patients with asthma.
Upon completion of this educational activity, the participant should be able to:
- Identify and address remediable causes of poor asthma control.
- Review the mechanism of action, efficacy, and safety of targeted agents approved for the management of severe, uncontrolled asthma with Type 2 inflammation and those in late-stage development.
- Incorporate agents targeted at Type 2 inflammation into the management of appropriate patients with severe, uncontrolled asthma not responding to ICS and bronchodilator therapy.
Dr. Kraft discloses the following:
Grants/Research Support: Chiesi USA, Sanofi
Consultant: AstraZeneca, Regeneron, Sanofi, Teva
Dr. Wechsler discloses the following:
Grants/Research Support: AstraZeneca, Novartis, Sanofi, Teva
Consultant: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Regeneron, Sanofi, Teva
Dr. DiMango discloses that her spouse is employed by Regeneron.
The planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of this continuing education activity hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
In this educational activity, the faculty reports that their presentation will not contain reference to investigational and/or off-label uses.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Academy of PAs and the American Association of Nurse Practitioners accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
Commercial Support Statements
This activity is supported by an educational grant from AstraZeneca.
© 2018 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.